Aim To in detail delineate sex differences non-small cell lung cancer outcome and investigate possible underlying drivers. Methods We performed a nationwide, population-based cohort study using data on all incident cases of squamous carcinoma (n = 10,325) adenocarcinoma 23,465) recorded the Swedish Lung Cancer Register 2002–2016. Flexible parametric models were applied to compute adjusted female-to-male hazard ratios (aHRs) standardized survival proportions over follow-up including age,...

It is well established that the male sex associated with increased risk for, as poorer survival of, most cancers. A similar pattern has been described in lymphomas but not yet comprehensively assessed. In this nationwide population-based cohort study, we used Swedish Lymphoma Register to investigate differences lymphoma subtype incidence and excess mortality adults (age 18-99) diagnosed 2000-2019. Male-to-female rate ratios (IRRs) (EMRs) adjusted for age calendar year were predicted using...

Helicobacter pylori infection is associated with a decreased risk of esophageal adenocarcinoma, and the decreasing prevalence such might contribute to increasing incidence this tumor. We examined hypothesis that eradication treatment H increases adenocarcinoma.

Studies from Western countries suggest that early-onset biliary tract cancer, a rare malignancy originating the bile ducts (cholangiocarcinoma) or gallbladder, is increasing. We performed population-based cohort study to outline age trends in cancer incidence Sweden.All patients with excluding non-biliary chiefly hepatocellular histopathology, recorded Swedish Cancer Register year 1993-2019 and at 20-84 were included. Analyses stratified by anatomical subtype; intrahepatic, perihilar,...

It is unknown if the reduction in expected number of cancer cases diagnosed during Swedish holidays are due to diagnostic delays, how different cancers affected, and season diagnosis influences long-term survival. We aimed quantify seasonal trends incidence excess mortality for a wide range malignancies, requiring more or less urgent clinical management.This nationwide cohort study included all residents aged 20-84 1990-2019. Incidence relative survival pancreatic, colorectal, lung,...

There is a lack of comprehensive reports on time trends in synchronous prostate and rectal cancers. To address this, we conducted the largest cohort study to date assess these population-based setting. We included all adult (ages 18-99) men with incident cancer Swedish Cancer Register 1993-2019. Age-standardized incidence rates (ASIRs) per 100,000 male population year were calculated compared ASIR (± 6 months from diagnosis) cancer. Age-adjusted synchronous-to-general rate ratios (IRRs)...

Advanced age is a consistent risk factor for cancer; nonetheless, cancer incidence typically declines after 75-85 most solid tumors.To delineate the true age-incidence pattern, we performed population-based cohort study using Swedish Cancer Register data from 1970-2014 on nine common, adult (age 20-99) cancers categorized as requiring high (pancreatic, lung, non-meningioma brain), medium (anorectal, urinary bladder, non-Hodgkin lymphoma), and low (melanoma skin, breast, prostate) diagnostic...

Early-onset adenocarcinomas of different sites are increasing in high-income countries, data on esophagogastric adenocarcinoma sparse.We performed a Swedish population-based cohort study over 1993 to 2019 delineate differences incidence and survival early-onset (age 20-54 years) compared with later-onset (55-99 esophageal, cardia, noncardia gastric adenocarcinoma. Temporal trends were quantified as annual percentage changes (APC) excess mortality rate ratios (EMRR) using Poisson regression...

The clinical importance of intraductal papillary mucinous neoplasm (IPMN) have increased last decades. Long-term survival after resection for invasive IPMN (inv-IPMN) compared to conventional pancreatic ductal adenocarcinoma (PDAC) is not thoroughly delineated.This study, based on the Swedish national and periampullary cancer registry aims elucidate outcome inv-IPMN PDAC.All patients ≥18 years age resected PDAC in Sweden between 2010 2019 were included. Clinicopathological variables...

BACKGROUND: Neoadjuvant cisplatin-based chemotherapy is standard care prior to radical cystectomy in patients with muscle-invasive bladder cancer (MIBC). OBJECTIVE: To assess efficacy and safety of two commonly used neoadjuvant schedules different total doses dose-intensities gemcitabine cisplatin (GC). METHODS: Data were collected retrospectively from all treated between 2010 2018 according clinical routine at seven centres Sweden Denmark. Patients received three cycles a 4-week schedule...

Incidence and mortality are default measures to describe cancer trends. Mortality compounds incidence survival but not age at death. We calculated years of life lost (YLL) due 1 the 10 solid tumors causing most deaths (lung, colorectal, prostate, pancreatic, breast, hepatobiliary, urinary, central nervous system, gastric, melanoma) using Swedish National Cancer Cause Death Registers. Comparing YLL with in 2019, lung (43 152 YLL) colorectal (32 340 remained top, pancreatic was upranked fourth...

Purpose This cohort description presents the Nordic Helicobacter Pylori Eradication Project (NordHePEP), a population-based of patients having received eradication treatment for pylori (HP). The is created with main purpose examining whether and to what extent HP influences risk gastrointestinal cancer.Participants NordHePEP includes all adults (aged ≥18 years) been prescribed dispensed according nationwide complete drug registries in any five countries (Denmark, Finland, Iceland, Norway, or...

<p>Early- (20-49) and later-onset (50-99) esophagogastric adenocarcinoma age-standardized incidence rate per 100,000 person-years by calendar period age-adjusted annual percentage change over 1993-2019, with 95% confidence intervals (CI).</p>

<p>Esophagogastric adenocarcinoma subtypes according to the International Classification of Diseases for Oncology 2nd revision (ICD-O-2).</p>

<p>Early- (age 20-54 years, solid) and later-onset 55-99 dashed line) esophagogastric adenocarcinoma excess mortality rate (EMR) per 1,000 person-years over 5 years from diagnosis.</p>

<p>Early- (age 20-54 years) and later-onset (55-99 esophagogastric adenocarcinoma incidence rate (IR) per 100,000 person-years over years 1993-2019, comparing empirical estimates (dots), modeled linear predictions with no breakpoint (blue solid line), together including one year (red line) identified using piecewise regression.</p>

<p>Sex distribution, numbers (n) and percentages (%) in early- (age 20-54 years) later-onset 55-84 esophagogastric adenocarcinoma patients diagnosed years 2007-2019.</p>

<p>Early-to-later-onset esophagogastric adenocarcinoma excess mortality rate ratios (EMRR) in patients diagnosed years 2007-2019, exploring effect modification by sex (upper panel) and cancer stage (lower panel), with 95% confidence intervals (CI), model fit compared using the likelihood-ratio test (p-value).</p>

<p>Early- (age 20-54 years) and later-onset 55-99 esophagogastric adenocarcinoma age-standardized incidence rate (ASIR) per 100,000 person-years in men (blue) women (red), presented as mean ASIR by calendar period, empirical estimates, modeled linear predictions over years 1993-2019.</p>

<p>Early- (20-49) and later-onset (50-99) esophagogastric adenocarcinoma age-standardized incidence rate per 100,000 person-years by calendar period age-adjusted annual percentage change over 1993-2019, with 95% confidence intervals (CI).</p>

<p>5-year relative survival in early- (age 20-49 years) and later-onset 50-84 esophagogastric adenocarcinoma diagnosed years 2007-2019 together with early-to-later-onset excess mortality rate ratios (EMRR) 95% confidence intervals (CI).</p>

<p>Distribution, numbers (n) and percentages (%), of clinicopathological characteristics in early- (age 20-49 years) later-onset 50-99 esophagogastric adenocarcinoma.</p>